Showing results (231-240 of 243) with videos related to
Sort By:
Pageof 25
The Journal of Clinical Endocrinology and Metabolism|January 1, 1997
Dimeric inhibins in amniotic fluid, maternal serum, and fetal serum in human pregnancyE M Wallace, S C Riley, J A Crossley, et al.Prenatal Diagnosis|April 21, 1999
Clinical follow-up of high mid-trimester maternal serum intact human chorionic gonadotrophin concentrations in singleton pregnanciesG Blundell, J P Ashby, C Martin, et al.Molecular Plant-Microbe Interactions : MPMI|April 15, 2005
Novel quorum-sensing-controlled genes in Erwinia carotovora subsp. carotovora: identification of a fungal elicitor homologue in a soft-rotting bacteriumC L Pemberton, N A Whitehead, M Sebaihia, et al.Current Oncology (Toronto, Ont.)|September 25, 2019
An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunctionC C Barron, M M Alhussein, U Kaur, et al.Science (New York, N.Y.)|June 4, 2021
Sense codon reassignment enables viral resistance and encoded polymer synthesisWesley E Robertson, Louise F H Funke, Daniel de la Torre, et al.Nature Communications|October 2, 2020
Genomics of the Argentinian cholera epidemic elucidate the contrasting dynamics of epidemic and endemic Vibrio choleraeMatthew J Dorman, Daryl Domman, Tomás Poklepovich, et al.Antonie Van Leeuwenhoek|November 27, 2002
The regulation of virulence in phytopathogenic Erwinia species: quorum sensing, antibiotics and ecological considerationsNeil A Whitehead, Joseph T Byers, Paul Commander, et al.Genome Announcements|December 17, 2013
Draft Genome Sequence of Serratia sp. Strain ATCC 39006, a Model Bacterium for Analysis of the Biosynthesis and Regulation of Prodigiosin, a Carbapenem, and Gas VesiclesPeter C Fineran, Marina C Iglesias Cans, Joshua P Ramsay, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2010
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24R Goodwin, K Ding, L Seymour, et al.Investigational New Drugs|February 6, 2020
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignanciesJ Nehra, P A Bradbury, P M Ellis, et al.Pageof 25